In 144 patients with rheumatoid arthritis in remission or low disease activity, neither ozoralizumab spacing (79.2%) nor methotrexate dose reduction (72.7%) was noninferior to continued treatment (97.9%) for keeping low disease activity at week 48.
RCTn = 144
Imai et al. Spacing of a TNF inhibitor or dose reduction of methotrexate vs continued treatment in patients with rheumatoid arthritis in remission or low disease activity: a randomised, controlled trial (SORAIRO trial)